InspireMD (NASDAQ: NSPR) and STAAR Surgical (NASDAQ:STAA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings and target prices for InspireMD and STAAR Surgical, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
InspireMD 0 0 0 0 N/A
STAAR Surgical 0 1 1 0 2.50

STAAR Surgical has a consensus price target of $12.00, indicating a potential upside of 1.27%. Given STAAR Surgical’s higher probable upside, analysts clearly believe STAAR Surgical is more favorable than InspireMD.

Valuation & Earnings

This table compares InspireMD and STAAR Surgical’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
InspireMD $2.00 million 1.19 -$8.37 million N/A N/A
STAAR Surgical $84.48 million 5.77 -$672,999.00 ($0.11) -107.73

STAAR Surgical has higher revenue and earnings than InspireMD.

Insider and Institutional Ownership

76.5% of STAAR Surgical shares are owned by institutional investors. 3.4% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares InspireMD and STAAR Surgical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
InspireMD -358.44% -136.76% -94.77%
STAAR Surgical -6.06% -8.69% -5.03%

Summary

STAAR Surgical beats InspireMD on 10 of the 10 factors compared between the two stocks.

InspireMD Company Profile

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

STAAR Surgical Company Profile

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery. It makes lenses used across the world in corrective or refractive surgery, and makes lenses for use in surgery that treats cataracts. Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). Its refractive surgery corrects the types of visual disorders that glasses or contact lenses have treated (myopia, hyperopia, astigmatism and presbyopia). As of December 30, 2016, it sold its products in more than 60 countries, with direct distribution in the United States, Canada, Japan and Spain, and independent distribution in the remainder of the world.

Receive News & Ratings for InspireMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InspireMD Inc and related companies with MarketBeat.com's FREE daily email newsletter.